Botti, G.; Collina, F.; Scognamiglio, G.; Rao, F.; Peluso, V.; De Cecio, R.; Piezzo, M.; Landi, G.; De Laurentiis, M.; Cantile, M.;
et al. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. Int. J. Mol. Sci. 2017, 18, 459.
https://doi.org/10.3390/ijms18020459
AMA Style
Botti G, Collina F, Scognamiglio G, Rao F, Peluso V, De Cecio R, Piezzo M, Landi G, De Laurentiis M, Cantile M,
et al. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. International Journal of Molecular Sciences. 2017; 18(2):459.
https://doi.org/10.3390/ijms18020459
Chicago/Turabian Style
Botti, Gerardo, Francesca Collina, Giosuè Scognamiglio, Federica Rao, Valentina Peluso, Rossella De Cecio, Michela Piezzo, Gabriella Landi, Michelino De Laurentiis, Monica Cantile,
and et al. 2017. "Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients" International Journal of Molecular Sciences 18, no. 2: 459.
https://doi.org/10.3390/ijms18020459
APA Style
Botti, G., Collina, F., Scognamiglio, G., Rao, F., Peluso, V., De Cecio, R., Piezzo, M., Landi, G., De Laurentiis, M., Cantile, M., & Di Bonito, M.
(2017). Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. International Journal of Molecular Sciences, 18(2), 459.
https://doi.org/10.3390/ijms18020459
